Download the Investor Thesis
The BioXcellerator Investor Thesis, March 2026. A comprehensive overview of the investment opportunity, financial highlights, and use of proceeds. Delivered immediately to your inbox.
BioXcellerator Investor Thesis
March 2026 \u00b7 Confidential \u00b7 For Qualified Investors Only
The BioXcellerator Investor Thesis provides a high-level overview of the investment opportunity — covering financial performance, use of proceeds, competitive positioning, and the strategic rationale for the raise. Enter your name and email below to receive the document immediately.
Investment Opportunity Overview
- Vertically integrated regenerative medicine platform
- 10+ years of operations, 50,000+ stem cell applications
- GCP-compliant clinical infrastructure across two countries
- Proprietary product pipeline: EVOKE exosomes, WJ-MSC cells, secretome
Financial Highlights
- $22.9M revenue (2025) with 85% gross margins
- Revenue growth from $8M (2020) to $30M projected (2026)
- Profitable operations throughout platform buildout
- EBITDA-positive with strong cash generation
Use of Proceeds
- U.S. Super Center buildout in Utah (SB 199 compliant)
- GMP manufacturing scale-up and CDMO capacity
- IP portfolio expansion and clinical trial funding
- Working capital and international market development
Competitive Positioning
- Dual ISO certifications (clinical + manufacturing)
- 66 IP assets · 1,500+ proprietary protocols
- 40+ U.S. healthcare provider referral network
- First-mover regulatory advantage in U.S. cell therapy market
Receive the Investor Thesis
Enter your full name and email address. The confidential thesis will be delivered to your inbox immediately.
By submitting, you confirm you are a qualified investor and consent to receive this confidential document by email. Not for public distribution.